ConductScience.org, home

Trial · NCT02049814

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12Baseline, Week 12
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline.
SecondaryChange From Baseline in HbA1c at Week 6Baseline and Week 6The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 6 relative to baseline.
SecondaryChange From Baseline in Fasting Blood Glucose Over TimeBaseline, Weeks 6 and 12The change between the fasting blood glucose value collected at weeks 6 and 12 or final visit relative to baseline.
SecondaryChange From Baseline in Postprandial Plasma Glucose (PPG) Over Time1 and 2 hours after meal at Baseline, Weeks 6 and 12The change between the value of glucose after 1 and 2 hours of meal, measured by the meal tolerance test collected at Weeks 6 and 12 or relative to baseline.
SecondaryChange From Baseline in Fasting Insulin at Week 12Baseline, Week 12The change between the fasting insulin value collected at week 12 or final visit relative to baseline.
SecondaryChange From Baseline in Postprandial Serum Insulin at Week 121 and 2 hours after meal at Baseline and Week 12The change from Baseline in postprandial serum insulin, after 1 and 2 hours of meal collected at Week 12 relative to baseline.
SecondaryChange From Baseline in Fasting Glucagon at Week 12Baseline, Week 12The change between the fasting glucagon value collected at week 12 or final visit relative to baseline.
SecondaryChange From Baseline in Postprandial Serum Glucagon at Week 121 and 2 hours after meal at Baseline and Week 12The change from Baseline in postprandial serum glucagon, after 1 and 2 hours of meal collected at Week 12 relative to baseline.
SecondaryChange From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12Baseline, Week 12
The change between the value of HOMA-IR collected at Week 12 and HOMA-IR collected at Baseline. HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance.
SecondaryChange From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA β) at Week 12Baseline, Week 12
The change between the value of HOMA-beta cell function collected at Week 12 and HOMA-beta cell function collected at Baseline. The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5.
SecondaryChange From Baseline in Body Weight Over TimeBaseline, Weeks 2, 6 and 12The change between body weight at weeks 2, 6 and 12 or relative to baseline.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02049814/registered